RPG Life Sciences has spun off its API business into a new subsidiary, RPG Active Pharma, securing a Rs 243.33 crore investment from InvAscent for a 40% stake. To drive growth, the new subsidiary is simultaneously acquiring Actis Generics and Raghava Life Sciences for a combined Rs 215 crore, aiming to boost capacity and portfolio depth with a zero-debt balance sheet.
RPG Life Sciences Restructures API Business with Strategic PE Partnership
- Rs 243.33 crore investment secured from InvAscent for 40% stake in RPG Active Pharma.
- Combined Rs 215 crore deployed to acquire Actis Generics and Raghava Life Sciences.
Reader Takeaway: This structural shift unlocks capital and capacity, positioning the API unit for aggressive, niche-focused growth.
What just happened
RPG Life Sciences has completed the subsidiarization of its API business into a dedicated entity, RPG Active Pharma (RPGAP). The move includes a major strategic partnership with pharma-focused Private Equity firm InvAscent, which will acquire a 40% stake in the subsidiary. Simultaneously, RPGAP is expanding its operational footprint by acquiring Actis Generics (Rs 80 crore) and Raghava Life Sciences (Rs 135 crore).
Why this matters
The restructuring transforms the API segment into an independent, well-capitalized business unit. By retaining a 60% stake, RPG Life Sciences maintains control while leveraging InvAscent's sectoral expertise. The integration of Actis Generics, which specializes in Anti-Diabetic and Cardiology segments, and Raghava Life Sciences, which brings a 300 KL capacity and 29 API molecules, provides an immediate scale-up in both product breadth and manufacturing capacity.
Strategic Outlook
Management aims to build a 'zero debt' business model within the new subsidiary, insulating it from commodity-price fluctuations by focusing on high-value, niche products. The acquisitions are expected to create significant cost and revenue synergies, supported by a newly appointed leadership team tasked with driving inorganic growth. The company expects the Raghava facility to reach a revenue potential of approximately Rs 200 crore at full capacity.
Risks to watch
Integration risks regarding the two newly acquired facilities could impact near-term margins. Furthermore, the success of this strategy depends on the subsidiary's ability to maintain high utilization rates at the acquired sites and successfully scale the niche API product pipeline in a competitive pharmaceutical market.
Context metrics
- RPG Life Sciences FY26 external API sales were approximately Rs 95.1 crore.
- The newly acquired Raghava Life Sciences facility spans 9 acres.